



ASX ANNOUNCEMENT

August 9, 2024

CHIMERIC PARTNERING WITH CELL THERAPIES AUSTRALIA

Sydney, Australia, 09 August 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce a collaboration with Cell Therapies Pty Ltd to explore the potential to manufacture Chimeric’s CAR T assets in Australia.

Cell Therapies Pty Ltd (“CTPL” or “Cell Therapies”) is an Australian based commercial contract development and manufacturing company, specialising in cell therapy, gene therapy, regenerative medicine, and cellular immunotherapy products. CTPL’s facilities are co-located with the Peter MacCallum Cancer Centre in Melbourne’s Parkville Precinct and are Australia’s only biomedical manufacturing facility where CAR T-cells and other “living” cancer therapies can be made at a commercial scale.

Chimeric currently has four Phase 1/1b trials open across the United States and is exploring the addition of new sites in Australia.

“This is great progress for Chimeric and aims to provide Australian patients with access to our first in class CAR T clinical trials,” said Dr Rebecca McQualter, Chief Operating Officer of Chimeric Therapeutics.

“We are very pleased to work with Chimeric to bring their innovative CAR T products to Australian cancer patients in need,” said Dr Bev Menner, Chief Executive Office of Cell Therapies.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.

To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers is focused on the discovery, development, and commercialisation of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.



CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.